Chemomab Therapeutics (NASDAQ:CMMB) Posts Quarterly Earnings Results, Misses Expectations By $0.18 EPS

Chemomab Therapeutics (NASDAQ:CMMB) announced its quarterly earnings results on Thursday. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.18), Zacks reports.

Chemomab Therapeutics Trading Down 2.4%

Shares of NASDAQ CMMB opened at $1.66 on Friday. Chemomab Therapeutics has a 12-month low of $1.35 and a 12-month high of $5.88. The company has a market cap of $11.94 million, a PE ratio of -0.75 and a beta of 0.51. The stock has a 50 day simple moving average of $1.71 and a 200-day simple moving average of $1.94.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Chemomab Therapeutics in a research report on Friday, May 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $25.00.

Hedge Funds Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. ADAR1 Capital Management LLC acquired a new position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 80,000 shares of the company’s stock, valued at approximately $132,000. ADAR1 Capital Management LLC owned about 1.30% of Chemomab Therapeutics at the end of the most recent reporting period. 46.05% of the stock is owned by hedge funds and other institutional investors.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.